Department of Surgery, Oncology and Gastroenterology, Hepatobiliary Surgery and Liver Transplantation Unit, Padova University Hospital, Padova, Italy.
Department of General & Digestive Surgery, Institut de Malalties Digestives I Metabòliques (IMDiM), Hospital Clínic, University of Barcelona, Spain.
Liver Int. 2019 May;39 Suppl 1(Suppl Suppl 1):143-155. doi: 10.1111/liv.14089.
Surgical resection is the only potentially curative treatment for patients with cholangiocarcinoma. For both perihilar cholangiocarcinoma (pCCA) and intrahepatic cholangiocarcinoma (iCCA), 5-year overall survival of about 30% has been reported in large series. This review addresses several challenges in surgical management of cholangiocarcinoma. The first challenge is diagnosis: a biopsy is typically avoided because of the risk of seeding metastases and the low yield of a brush of the bile duct. However, about 15% of patients with suspected pCCA are found to have a benign diagnosis after resection. The second challenge is staging; even with the best preoperative imaging, a substantial percentage of patients has occult metastatic disease detected at staging laparoscopy or early recurrence after resection. The third challenge is an adequate volume and function of the future liver remnant, which may require preoperative biliary drainage and portal vein embolization. The fourth challenge is a complete resection: a positive bile duct margin is not uncommon because the microscopic biliary extent of disease may be more extensive than perceived on imaging. The fifth challenge is the high post-operative mortality that has decreased in very high volume Asian centres, but remains about 10% in many Western referral centres. The sixth challenge is that even after a complete resection most patients develop recurrent disease. Recent randomized controlled trials found conflicting results regarding the benefit of adjuvant chemotherapy. The final challenge is to determine which patients with cholangiocarcinoma should undergo liver transplantation rather than resection.
手术切除是胆管癌患者唯一有治愈可能的治疗方法。对于肝门部胆管癌(pCCA)和肝内胆管癌(iCCA),在大型系列研究中,约有 30%的患者报告了 5 年总生存率。这篇综述探讨了胆管癌手术治疗中的几个挑战。第一个挑战是诊断:由于种植转移的风险和胆管刷取的低产量,通常避免进行活检。然而,约 15%的疑似 pCCA 患者在切除后被发现诊断为良性。第二个挑战是分期;即使术前影像学检查最好,仍有相当一部分患者在分期腹腔镜检查或切除后早期复发时发现隐匿性转移疾病。第三个挑战是未来肝剩余部分的足够体积和功能,这可能需要术前胆道引流和门静脉栓塞。第四个挑战是完整切除:胆管边缘阳性并不少见,因为疾病的微观胆管范围可能比影像学上观察到的更广泛。第五个挑战是高术后死亡率,在高容量的亚洲中心有所下降,但在许多西方转诊中心仍约为 10%。第六个挑战是,即使进行了完整切除,大多数患者仍会出现复发性疾病。最近的随机对照试验发现辅助化疗的益处存在矛盾的结果。最后一个挑战是确定哪些胆管癌患者应该进行肝移植而不是切除。